Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.
Klocker EV et al.
Npj Breast Cancer, 2025
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.
Yasin F et al.
The Oncologist, 2024
Variation Analysis in Premenopausal and Postmenopausal Breast Cancer Cases.
Erdogdu IH et al.
Journal of Personalized Medicine, 2024
Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Martínez-Nava GA et al.
Diagnostics (basel, Switzerland), 2024
Whole-exome sequencing of rectal neuroendocrine tumors.
Li Y et al.
Endocrine-related Cancer, 2023
Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort.
Pipek O et al.
International Journal of Molecular Sciences, 2023
Genetic Characterization of Ovarian Tumor Tissues from Patients with Epithelial Ovarian Cancer in a Philippine Tertiary Hospital: A Descriptive Study.
Lintao RCV et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2023
Genetic landscape and personalized tracking of tumor mutations in Vietnamese women with breast cancer.
Nguyen Hoang VA et al.
Molecular Oncology, 2023
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations.
Soria-Bretones I et al.
Science Advances, 2022
Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC.
Cooper AJ et al.
Jto Clinical and Research Reports, 2022
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Pascual J et al.
Cancer Discovery, 2021
Long-read sequencing for non-small-cell lung cancer genomes.
Sakamoto Y et al.
Genome Research, 2020
Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC).
Saba NF et al.
Plos One, 2020
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
Langer CJ et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2019
Targeted deep sequencing from multiple sources demonstrates increased NOTCH1 alterations in lung cancer patient plasma.
Liao Y et al.
Cancer Medicine, 2019
Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma.
Nakagaki T et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2018
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Hasegawa K et al.
Investigational New Drugs, 2017
Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks.
Murakami R et al.
The American Journal of Pathology, 2017
Development and clinical application of an integrative genomic approach to personalized cancer therapy.
Uzilov AV et al.
Genome Medicine, 2016
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.
Pereira B et al.
Nature Communications, 2016
Somatic mutation in PIK3CA is a late event in cervical carcinogenesis.
Verlaat W et al.
The Journal of Pathology. Clinical Research, 2015
Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.
Millis SZ et al.
Clinical Genitourinary Cancer, 2015
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
Wright AA et al.
Cancer, 2013
Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
Ross JS et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women.
Cui B et al.
International Journal of Oncology, 2009